Drugs Archives – Treatment Action Group

Open Letter: Urgent Action Necessary to Improve Equitable Access to Bedaquiline-Based Regimens and Achieve 1/4/6×24

January 13, 2023
Dorrit Walsh

TAG and a coalition of civil society activists, public health leaders, and researchers acting in solidarity with communities affected by tuberculosis sent an open letter to Johnson & Johnson calling on the company to publicly commit to withdraw and not…

Response to Tuberculosis Treatment Trials Results Published and Presented During the 2022 Union World Conference on Lung Health

November 16, 2022
Dorrit Walsh

Treatment Action Group (TAG) and the Global Tuberculosis Community Advisory Board (TB CAB) welcome the clinical trials results recently published and presented during the 2022 Union World Conference on Lung Health, which evaluated shorter regimens and treatment shortening strategies for drug-sensitive and drug-resistant tuberculosis.

image that reads: Introduction: 1/4/6 x24 - a campaign to rally energy, political will & funding to end TB

1/4/6×24 Community Campaign Training Materials

November 11, 2022
Dorrit Walsh

Community engagement and mobilization will be key to winning equitable access to the short-course treatment and prevention regimens at the heart of the 1/4/6x24 Campaign. For everyone to benefit from the scientific progress that made these effective new preventive treatments…

Storytelling to Support TB Preventive Treatment (TPT)

October 24, 2022
Dorrit Walsh

Storytelling is a tool that can help build understanding, support discussions between members of affected communities and other stakeholders, and aid in the identification of important issues and potential solutions. The storyboards on this page describe the experiences of people…

The LAT CAB Responds to MedinCell and Medicines Patent Pool License on a New Long-Acting Malaria Formulation

September 21, 2022
Dorrit Walsh

As the global Long-Acting Technologies Community Advisory Board (LAT CAB) representing vast civil society networks, and people living with and affected by malaria, HIV, tuberculosis, and the hepatitis C virus (HCV) across the world, we welcome the efforts leading to the development of an investigational long-acting injectable (LAI) formulation of ivermectin to fight malaria transmission, mdc-STM currently in preclinical stage, and developed by MedinCell.

Activists Across the World Demand Urgent Action to Improve Access to Lifesaving Tuberculosis (TB) Medicine, Bedaquiline

July 1, 2022
Dorrit Walsh

A new generic version of bedaquiline produced by Macleods Pharmaceuticals in India has cleared the Global Fund’s Expert Review Panel (ERP), an independent group of experts that reviews finished pharmaceutical products and makes recommendations on their use to the Global Fund.

Joint Statement from Leading HIV/AIDS and Viral Hepatitis Advocates regarding Manufacturer Action on the 340B Drug Pricing Program

April 20, 2022
Dorrit Walsh

A group of six leading HIV/AIDS and viral hepatitis advocates today released the following joint statement regarding recent manufacturer action against the 340B Drug Pricing Program:

Test and Treat COVID-19: Community Guide to Molnupiravir

April 20, 2022
Dorrit Walsh

This factsheet developed by IMPAACT4C19 and Treatment Action Group lays out all that you need to know about molnupiravir: what it is, how to take it, who should use it (and who should not,) and how it interacts with other drugs.

HIV Updates From CROI: The Good, the Bad, and the Long-Acting

March 29, 2022
Dorrit Walsh

On April 15 TAG presented, "HIV Updates From CROI: The Good, the Bad, and the Long-Acting." This free webinar unpacked the most significant developments in HIV research presented at the Conference on Retroviruses and Opportunistic Infection (CROI), and what they mean for communities affected by HIV.

CROI 2022 TB Round Up

March 22, 2022
Dorrit Walsh

Treatment Action Group welcomes the tuberculosis (TB) data reported at the 2022 Conference on Retroviruses and Opportunistic Infections (CROI). This is a summary of major findings — and TAG’s take on them.